HER2, a family member of the ERBB transmembrane receptor tyrosine kinases (ERBB1-4 or also known as EGFR and HER2-4) is a well-known target in HER2-amplified breast cancer therapy for both primary tumors (266, 267) and metastases (268–270). The gene discussed is EGFR; the disease is breast carcinoma.